Business Award - April 1, 2026
The first recipient of the NADMED Award
NADMED has selected a research project from the Schlegel Lab at Cleveland Clinic in Ohio, which could improve how donor organs are preserved and assessed before transplantation, as the first recipient of the USD 30,000 award.
Clinical Trials - April 1, 2026
Cereno Scientific reports 12-month data
The company has announced initial learnings from the 12-month Expanded Access Program (EAP) with its lead drug candidate CS1 in pulmonary arterial hypertension (PAH).
Funding - April 1, 2026
SEK 1.6 billion allocated to life science with focus on clinical research
Knut and Alice Wallenberg Foundation is allocating additional funds to patient‑oriented, clinical research.
Clinical Trials - March 31, 2026
Affibody reports positive Phase 3 data
The company has announced positive 32-week data from a global Phase 3 study of the next generation IL-17A inhibitor izokibep in hidradenitis suppurativa (HS).
Acquisition - March 30, 2026
Insilico Medicine and Lilly enter R&D collaboration
Insilico Medicine has announced a drug discovery collaboration with Eli Lilly and Company (Lilly) that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.
Biotech Business - March 27, 2026
Sprint Bioscience publishes new research findings
Sprint Bioscience is taking further steps in its DCPS program through a new study that reinforces the scientific support for DCPS inhibition as a promising treatment strategy for acute myeloid leukemia (AML).
